PharmmaEx Expo 2024: Bangalore Set to Host Largest Pharma Expo from Feb 2

Bangalore (Karnataka) [India], January 18: PharmmaEx Expo, the eminent annual rendezvous of pharmaceutical brilliance will be held at the Manpho Convention Center, Bengaluru from February 2 to 3.  This three-day event will focus on third-party manufacturing including PCD franchises while showcasing the capabilities of the Indian pharmaceutical industry through various innovations, technology and products. This distinguished event, boasting over 150 exhibitors, is set to draw over 10,000 professionals and enthusiasts from the pharmaceutical industry.

With the domestic pharmaceutical industry projected to reach $57 billion by FY25, coupled with an expansion in operating margins by 100-150 basis points (bps), PharmmaEx Expo 2024 aligns seamlessly with the industry’s upward trajectory.

A recent report by CareEdge Ratings underscores the robust growth of the Indian pharmaceutical industry. With a compound annual growth rate (CAGR) of 6-8% during FY18 to FY23, driven by an 8% increase in exports and a 6% rise in the domestic market, the sector exhibits resilience and strategic expansion.

Shivam Sharma, Director of Devasya Media (The event organising company) emphasized the event’s significance amid these market dynamics: “PharmmaEx Expo serves as a dynamic platform, fostering collaboration and innovation in the pharmaceutical sector. Against the backdrop of industry growth and evolving trends, the expo becomes a nexus for stakeholders to explore opportunities and navigate the changing landscape.”

In FY23, the Indian pharma market witnessed a remarkable year-on-year growth of nearly 5%, reaching $49.78 billion. Notably, exports grew modestly by 3%, while the domestic market surged by 7% year-on-year. Developed markets recorded an 8% growth, overcoming challenges posed by the Russia-Ukraine conflict, scarcity of foreign currency in several African countries, and significant depreciation of local currencies in emerging markets.

PharmmaEx Expo 2024 promises to showcase the latest advancements in pharmaceuticals, healthcare, and related technologies. With participation from over 150 exhibitors, the event assures an immersive experience for attendees eager to explore the forefront of pharmaceutical breakthroughs.

The Indian pharmaceutical sector’s anticipated steady growth in the medium term is attributed to structural factors such as the ageing population, a rise in lifestyle-related chronic diseases, increasing healthcare awareness, insurance penetration, and augmented government spending under various schemes. Additionally, the changing global demography and the proliferation of complex and speciality generic products are poised to propel the export growth of Indian pharma companies. This growth will be further bolstered by patent expires in regulated markets.

For more information, Kindly Visit https://pharmmaex.com/

If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.

Business

Fischer Medical Subsidiary, Time Medical India, Collaborates with Dr. Cherian to Pioneer Next-Generation AI-Enabled MRI System

Mumbai (Maharashtra) [India], November 4: Fischer Medical Ventures Limited (FISCHER | 524743 | INE771F01041), Time Medical International Ventures (I) P LTD, the wholly owned subsidiary of Fischer Medical Ventures Limited, today announced a strategic collaboration with globally acclaimed neurosurgeon, educator, and innovator Dr Iype Cherian. The collaboration’s sole purpose is the development of DRIS–iMRI Medharanya, a […]

Read More
Agartala Business Dr. Saikat Kar innovation Neurotech Startup Science

From Agartala to Global Innovation: How Tripura’s First Neurotech Startup is Bridging Brain Science with Grassroots Impact

Agartala (Tripura) [India], November 4: In a region celebrated for tea gardens and handicrafts rather than technological ambition, a quiet revolution is unfolding. Codonmind Nexus Private Limited, the Northeast’s pioneering neurotechnology startup, is developing brain-computer interface devices and advanced neurological research tools positioned to compete with national players in a market projected to reach USD […]

Read More
Business Harsheep Hortico Limited

Harshdeep Hortico Reports Strong H1 FY26 with Net Profit of INR 5.7 crore

Mumbai (Maharashtra) [India], November 4: Harsheep Hortico Limited (BSE: HARSHDEEP), specializing in the manufacture and export of pots, planters, garden accessories, and outdoor furniture; announced its Unaudited financials for H1 FY26. Key H1 FY25 Financial Highlights Key Financial Highlights (Consolidated) – H1 FY2025-26 Revenue for H1 FY2025–26 was ₹37.84 crore, compared to ₹24.09 crore in […]

Read More